MicroRNAs (miRNAs) participate in the regulation of cardiac hypertrophy. However, it remains largely unknown as to how miRNAs are integrated into the hypertrophic program. Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a hypertrophic signaling marker. It is not yet clear which miRNAs can regulate CaMKIIδ.
Purpose
In this study, we identified which miRNAs could regulate CaMKIIδ and how to regulate CaMKIIδ.
Methods
Through computational and expression analyses, miR-30b-5p was identified as a candidate regulator of CaMKIIδ. Quantitative expression analysis of hypertrophic models demonstrated significant down-regulation of miR-30b-5p compared with control groups. Luciferase reporter assay showed that miR-30b-5p could significantly inhibit the expression of CaMKIIδ. Moreover, through gain-of-function and loss-of-function approaches, we found miR-30b-5p could negatively regulate the expression of CaMKIIδ and miR-30b-5p was a regulator of cardiac hypertrophy.
Conclusion
Our study demonstrates that the expression of miR-30b-5p is down-regulated in cardiac hypertrophy, and restoration of its function inhibits the expression of CaMKIIδ, suggesting that miR-30b-5p may act as a hypertrophic suppressor.
RuilopeLM, SchmiederRE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008; 21: 500–508.
2.
FreyN, OlsonEN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003; 65: 45–79.
3.
HeinekeJ, MolkentinJD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006; 7: 589–600.
4.
LingH, ZhangT, PereiraL, . Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009; 119: 1230–1240.
5.
KushnirA, ShanJ, BetzenhauserMJ, . Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci U S A. 2010; 107: 10274–10279.
6.
BraunAP, SchulmanH. The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. Annu Rev Physiol. 1995; 57: 417–445.
TombesRM, FaisonMO, TurbevilleJM. Organization and evolution of multifunctional Ca(2+)/CaM-dependent protein kinase genes. Gene. 2003; 322: 17–31.
9.
HochB, MeyerR, HetzerR, . Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ Res. 1999; 84: 713–721.
10.
ColomerJM, MaoL, RockmanHA, . Pressure overload selectively up-regulates Ca2+/calmodulin-dependent protein kinase II in vivo. Mol Endocrinol. 2003; 17: 183–192.
11.
BacksJ, BacksT, NeefS, . The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009; 106: 2342–2347.
12.
ZhangT, JohnsonEN, GuY, . The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 2002; 277: 1261–1267.
13.
ZhangT, MaierLS, DaltonND, . The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003; 92: 912–919.
14.
ZhangR, KhooMS, WuY, . Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11: 409–417.
15.
PauleyKM, EystathioyT, JakymiwA, . Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep. 2006; 7: 904–910.
KovacicS, SoltysCL, BarrAJ, . Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem. 2003; 278: 39422–39427.
25.
NicolRL, FreyN, PearsonG, . Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001; 20: 2757–2767.
26.
LeeRC, FeinbaumRL, AmbrosV. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843–854.
27.
van RooijE, SutherlandLB, LiuN, . A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006; 103: 18255–18260.
28.
SayedD, HongC, ChenIY, . MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007; 100: 416–424.
29.
McKinseyTA. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res. 2007; 73: 667–677.
30.
FielitzJ, KimMS, SheltonJM, . Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci U S A. 2008; 105: 3059–3063.
31.
MolkentinJD, LuJR, AntosCL, . A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215–228.
32.
VegaRB, HarrisonBC, MeadowsE, . Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004; 24: 8374–8385.
33.
ZhangW, QiF, ChenDQ, . Ca2+/calmodulin-dependent protein kinase IIdelta orchestrates G-protein-coupled receptor and electric field stimulation-induced cardiomyocyte hypertrophy. Clin Exp Pharmacol Physiol. 2010; 37: 795–802.
34.
MaierLS. CaMKIIdelta overexpression in hypertrophy and heart failure: cellular consequences for excitation-contraction coupling. Braz J Med Biol Res. 2005; 38: 1293–1302.
35.
Le GuillouS, SdassiN, LaubierJ, . Overexpression of miR-30b in the developing mouse mammary gland causes a lactation defect and delays involution. PLoS One. 2012; 7: e45727.
36.
WuT, ZhouH, HongY, . miR-30 family members negatively regulate osteoblast differentiation. J Biol Chem. 2012; 287: 7503–7511.
37.
ZaragosiLE, WdziekonskiB, BrigandKL, . Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol. 2011; 12: R64.
38.
LiJ, DonathS, LiY, . miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010; 6: e1000795.
39.
BraunJ, Hoang-VuC, DralleH, . Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010; 29: 4237–4244.
40.
ZhangJ, ZhangH, LiuJ, . miR-30 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun. 2012; 417: 1100–1105.
41.
MartinezI, CazallaD, AlmsteadLL, . miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci U S A. 2011; 108: 522–527.
42.
YuF, DengH, YaoH, . Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010; 29: 4194–4204.
43.
DuistersRF, TijsenAJ, SchroenB, . miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009; 104: 170–178, 176p following 178.
44.
DongS, ChengY, YangJ, . MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. 2009; 284: 29514–29525.
BoutzPL, ChawlaG, StoilovP, . MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev. 2007; 21: 71–84.
51.
BaekD, VillenJ, ShinC, . The impact of microRNAs on protein output. Nature. 2008; 455: 64–71.
52.
SelbachM, SchwanhausserB, ThierfelderN, . Widespread changes in protein synthesis induced by microRNAs. Nature. 2008; 455: 58–63.
53.
ZhangT, MiyamotoS, BrownJH. Cardiomyocyte calcium and calcium/calmodulin-dependent protein kinase II: friends or foes?Recent Prog Horm Res. 2004; 59: 141–168.
54.
IkedaS, HeA, KongSW, . MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009; 29: 2193–2204.
55.
CordesKR, SheehyNT, WhiteMP, . miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009; 460: 705–710.
